Stifel 2025 Healthcare Conference November 12, 2025 4:40 PM ESTCompany ParticipantsRachel McMinn - Founder, Executive Chair ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback